Home › Soft Tissue Sarcoma › Virginia
Soft Tissue Sarcoma clinical trials in Virginia
7 studies for Soft Tissue Sarcoma are looking for participants at sites in Virginia.
Cities in Virginia
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- University of Virginia Cancer Center, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05711615Distance-Based Exercise to Preserve Function and Prevent Disability
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- Bon Secours Saint Mary's Hospital, Richmond
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- NEXT Oncology, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06975293Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Next Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- University of Virginia, Charlottesville
- NEXT Oncology - Virginia, Fairfax
RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
- Zai Lab Site 02006, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07374848A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2025 · NCT04370587From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.